Roxadustat: First Global Approval
- 282 Downloads
Roxadustat (Ai Rui Zhuo® in China) is an orally administered, small molecule hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor that is being developed by FibroGen, in collaboration with Astellas and AstraZeneca, for the treatment of anaemia in patients with dialysis-dependent chronic kidney disease (CKD), non-dialysis-dependent CKD and in patients with myelodysplastic syndromes. The drug reversibly binds to and inhibits HIF-prolyl hydroxylase enzymes that are responsible for the degradation of transcription factors in the HIF family under normal oxygen conditions. Inhibition of these enzymes reduces HIF breakdown and promotes HIF activity, leading to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. It also reduces the expression of the peptide hormone hepcidin, improves iron availability and increases haemoglobin levels. HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism. Roxadustat is approved in China and is under regulatory review in Japan for the treatment of anaemia in patients with dialysis-dependent CKD. Studies are underway to investigate long-term cardiovascular outcomes with roxadustat versus placebo (for non-dialysis-dependent CKD) or standard of care (for dialysis-dependent CKD). This article summarizes the milestones in the development of roxadustat leading to this first approval.
Compliance with Ethical Standards
The preparation of this review was not supported by any external funding.
Conflict of interest
During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.
- 6.FibroGen. FibroGen announces approval of roxadustat in China for the treatment of anemia in chronic kidney disease patients on dialysis [media release]. 17 Dec 2018. http://investor.fibrogen.com/phoenix.zhtml?c=253783&p=irol-newsArticle&ID=2380952.
- 7.FibroGen. FibroGen enters agreement with Yamanouchi to license erythropoietic small molecule in development for the treatment of anemia [media release]. 24 Sep 2004. http://investor.fibrogen.com/phoenix.zhtml?c=253783&p=irol-newsArticle&ID=1984318.
- 8.FibroGen. FibroGen licenses oral HIF-PH inhibitors, including FG-2216 and FG-4592, to Astellas for the treatment of anemia in Europe and other regions; FibroGen positioned to develop first oral anemia therapy for North America [media release]. 28 Apr 2006. http://investor.fibrogen.com/phoenix.zhtml?c=253783&p=irol-newsArticle&ID=1984254.
- 9.FibroGen. FibroGen announces initiation of phase 2b studies of FG-4592, an oral HIF prolyl hydroxylase inhibitor, for treatment of anemia in chronic kidney disease [media release]. 17 Mar 2011. http://investor.fibrogen.com/phoenix.zhtml?c=253783&p=irol-newsArticle&ID=1983440.
- 10.AstraZeneca. AstraZeneca and FibroGen collaborate to develop and commercialize FG-4592, a treatment for anemia in chronic kidney disease and end-stage renal disease [media release]. 31 Jul 2013. https://www.astrazeneca.com/media-centre/press-releases/2013/astrazeneca-fibrogen-fg4592-anaemia-treatment-chronic-kidney-disease-renal-disease-31072013.html#.
- 11.FibroGen. FibroGen announces receipt of $62 million license payment from AstraZeneca [media release]. 8 Jul 2016. http://investor.fibrogen.com/phoenix.zhtml?c=253783&p=irol-newsArticle&ID=2182906.
- 12.FibroGen. FibroGen announces receipt of $120 million license payment from AstraZeneca [media release]. 29 Jun 2015. http://investor.fibrogen.com/phoenix.zhtml?c=253783&p=irol-newsArticle&ID=2063398.
- 13.FibroGen. FibroGen’s roxadustat (FG-4592) meets primary endpoints in two phase 3 anemia studies in China [media release]. 30 Jan 2017. http://investor.fibrogen.com/phoenix.zhtml?c=253783&p=irol-newsArticle&ID=2240513.
- 14.FibroGen Inc. SEC Filings: form 10-K. 2018. http://phx.corporate-ir.net/phoenix.zhtml?c=253783&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTEyMDg4MDE4JkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3. Accessed 2018.
- 19.Yu KH, Chou J, Klaus S, et al. Comparable doses of FG-4592 have similar PK/PD in healthy Caucasian and Japanese subjects (abstract no. MP204). Nephrol Dial Transplant. 2013;28(Suppl 1):i362.Google Scholar
- 20.Chen X, Zheng X, Jiang J, et al. FG4592, a novel inhibitor of the prolyl hydroxylase of hypoxia-inducible factor (HIF-PH) elicited linear-exponential dose-response profile on plasma erythropoietin (EPO) levels (abstract no. P413). Haematologica. 2013;98(Suppl 1):175–6.Google Scholar
- 21.Shibata T, Nomura Y, Takada A, et al. Evaluation of food and spherical carbon adsorbent effects on the pharmacokinetics of roxadustat in healthy nonelderly adult male Japanese subjects. Clin Pharmacol Drug Dev. 2018. https://doi.org/10.1002/cpdd.597.
- 22.Groenendaal-van de Meent D, Adel MD, Noukens J, et al. Effect of moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of roxadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Clin Drug Investig. 2016;36(9):743–51.Google Scholar
- 23.Groenendaal-van de Meent D, den Adel M, van Dijk J, et al. Effect of multiple doses of omeprazole on the pharmacokinetics, safety, and tolerability of roxadustat in healthy subjects. Eur J Drug Metab Pharmacokinet. 2018. https://doi.org/10.1007/s13318-018-0480-z.
- 25.Groenendaal-van de Meent D, den Adel M, Rijnders S, et al. The hypoxia-inducible factor prolyl-hydroxylase inhibitor roxadustat (FG-4592) and warfarin in healthy volunteers: a pharmacokinetic and pharmacodynamic drug-drug interaction study. Clin Ther. 2016;38(4):918–28.Google Scholar
- 26.FibroGen. FibroGen announces positive topline results from three global phase 3 trials of roxadustat for treatment of anemia in patients with chronic kidney disease: primary efficacy endpoints met in all three studies, non-dialysis, incident dialysis, and stable dialysis studies [media release]. 20 Dec 2018. http://investor.fibrogen.com/phoenix.zhtml?c=253783&p=irol-newsArticle_print&ID=2381297.
- 27.Chen N, Hao C-M, Liu B-C, et al. A phase 3, randomized, open-label, active-controlled study of efficacy and safety of roxadustat for treatment of anemia in subjects with CKD on dialysis (abstract no. TH-PO1152). J Am Soc Nephrol. 2018;29(Suppl):B5.Google Scholar
- 28.Akizawa T, Iwasaki M, Yamaguchi Y, et al. Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) conversion study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan (abstract no. TH-PO1151). J Am Soc Nephrol. 2018;29(Suppl):B4–B5.Google Scholar
- 29.Akizawa T, Otsuka T, Reusch M, et al. Phase 3, multicenter, open-label study of intermittent oral roxadustat in peritoneal dialysis CKD patients with anemia (abstract no. SA-OR075). J Am Soc Nephrol. 2018;29(Suppl):99.Google Scholar
- 30.AstraZeneca. Phase III OLYMPUS and ROCKIES trials for roxadustat met their primary endpoints in chronic kidney disease patients with anaemia [media release]. 2018. https://www.astrazeneca.com/media-centre/press-releases/2018/phase-iii-olympus-and-rockies-trials-for-roxadustat-met-their-primary-endpoints-in-chronic-kidney-disease-patients-with-anaemia20122018.html.
- 31.Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016;67(6):912–24.CrossRefGoogle Scholar
- 33.Astellas Pharma. Astellas announces positive topline results for global phase 3 trial of roxadustat in chronic kidney disease (CKD) patients with anemia not on dialysis [media release]. 20 Sep 2018. https://www.astellas.com/system/files/news/2018-09/180920_eg.pdf.
- 34.Chen N, Hao C-M, Peng X, et al. A phase 3, randomized, double-blind, placebo-controlled study of efficacy and safety of roxadustat (FG-4592) for treatment of anemia in subjects with CKD not on dialysis (abstract no. TH-PO1153). J Am Soc Nephrol. 2018;29(Suppl.):B5.Google Scholar